Obesity drug UBT251 put to the test: will it clash with common meds?

NCT ID NCT07710768

Not yet recruiting Knowledge-focused Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

First seen Jul 17, 2026 · Last updated Jul 17, 2026

Summary

This study investigates whether UBT251, an experimental drug for overweight or obesity, changes how the body processes other medications like warfarin, caffeine, and midazolam. Researchers will give UBT251 to 44 adults with a BMI between 27 and 39.9, then measure levels of these other drugs in the blood. The goal is to ensure UBT251 can be safely combined with common medicines without causing harmful interactions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: UBT251 and a cocktail of warfarin, caffeine, and midazolam
What this could lead to: If successful, this could show that UBT251 is safe to use alongside common medications, paving the way for broader obesity treatments.
What could go wrong: This is an early-phase study with only 44 participants, so results may not apply to everyone. Drug interactions could still occur in real-world use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY OVERWEIGHT

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Altasciences Clinical LA, Inc.

Cypress, California, 90630, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.